Mobile Menu - OpenMobile Menu - Closed

Full Committee:Trump Administration's Response to the Drug Crisis

Date: 
Thursday, March 7, 2019 - 10:00am
Location: 
2154 Rayburn House Office Building, Washington, DC 20515
Trump Administration's Response to the Drug Crisis

 

PURPOSE

The hearing will examine ONDCP’s coordination of national drug control efforts, including the Administration’s response to the opioid crisis.  The hearing will also examine ONDCP’s implementation of the provisions of the SUPPORT for Patients and Communities Act that reauthorized the agency.

BACKGROUND

  • According to the Centers for Disease Control and Prevention (CDC), “In 2017, there were 70,237 drug overdose deaths in the United States.” This is the highest rate of drug overdose deaths ever observed in the United States.

  • For two years, the Trump Administration had no drug control strategy—even though the Administration was required by law to issue an annual strategy in both 2017 and 2018.

  • On January 31, 2019, the Trump Administration finally issued its first National Drug Control Strategy, but it was woefully inadequate and fails to comply with numerous provisions in the law.

  • For two years, the Trump Administration had no permanent ONDCP Director.  James Carroll was confirmed on January 2, 2019, but appears to have little experience in drug control policy.

 

​Chairman Cummings Opening Statement

 

WITNESSES

The Honorable James W. Carroll Jr.
Director, Office of National Drug Control Policy

Mr. Mike McDaniel
Director, Houston High Intensity Drug Trafficking Area

Ms. Triana McNeil
Acting Director, Strategic Issues, Government Accountability Office

116th Congress